- Open Access
Identification of Ser465 as a novel PINK1 autophosphorylation site
© The Author(s). 2017
- Received: 18 September 2017
- Accepted: 28 November 2017
- Published: 14 December 2017
PINK1 (PTEN-induced putative kinase 1) gene is the causal gene for recessive familial type 6 of Parkinson’s disease (PARK6), which is an early-onset autosomal recessive inherited neurodegenerative disease. PINK1 has been reported to exert both autophosphorylation and phosphorylation activity, affecting cell damage under stress and other physiological responses. However, there has been no report on the identification of PINK1 autophosphorylation sites and their physiological functions.
(1) We adopted mass spectrometry assay to identify the autophosphorylation site of PINK1, and autoradiography assay was further conducted to confirm this result. (2) Kinase activity assay was used to compare the kinase activity of both Ser465 mutant PINK1 and disease-causing mutant PINK1. (3) We use Pulse-chase analysis to measure whether Ser465 may affect PINK1 degradation. (4) Immunocytochemistry staining was used to study the PINK1 subcellular localization and Parkin transition in subcellular level.
In our study, we identified the 465th serine residue (Ser465) as one of the autophosphorylation sites in PINK1 protein. The inactivation of Ser465 can decrease the kinase activity of PINK1. Either dissipated or excessive Ser465 site phosphorylation of PINK1 can slow down its degradation. PINK1 autophosphorylation contributes to the transit of Parkin to mitochondria, and has no effect on its subcellular localization. PARK6 causal mutations, T313 M and R492X, display the same characteristics as Ser465A mutation PINK1 protein, such as decreasing PINK1 kinase activity and affecting its interaction with Parkin.
Ser465 was identified as one of the autophosphorylation sites of PINK1, which affected PINK1 kinase activity. In addition, Ser465 is involved in the degradation of PINK1 and the transit of Parkin to mitochondria. T313 M and R492X, two novel PARK6 mutations on Thr313 and Arg492, were similar to Ser465 mutation, including decreasing PINK1 phosphorylation activity and Parkin subcellular localization.
- Parkinson’s disease
- Autophosphorylation sites
- Kinase activity
Parkinson’s disease (PD) is one of the most pervasive neurodegenerative diseases. Currently, the etiology and mechanism of PD are not fully clear. But, aging, environmental and genetic factors appear to play the key role in PD [2, 7, 21].
PINK1 (PTEN-induced putative kinase 1) gene is the causative gene for PARK6, which was cloned in 2004 by Valente et al. . Encoded by the PINK1 gene, PINK1 protein contains 581 amino acids, including a mitochondrial localization domain (34 amino acids) and a serine/threonine kinase domain (354 amino acids). The kinase domain (KD) is highly conserved, capable of catalyzing by binding to the peptide substrate and transferring ATP phosphate group . Recent studies showed that PINK1 may directly phosphorylate other proteins, exerting anti-oxidative stress and anti-apoptosis effects. TRAP1 protein is found to be the substrate of PINK1 , through which, PINK1 can reduce the release of mitochondrial cytochrome c and fill the gap caused by cell damage and even cell death under stress. In 2008, Kim et al.  found that PINK1 can phosphorylate Parkin directly, regulating their transfer to the mitochondria. In addition, PINK1 kinase domain possesses both autophosphorylation  and phosphorylation activity in vitro, such as phosphorylating histone H1 or casein [17, 18]. In our previous work, we found two novel PINK1 homozygous disease-causing mutations (T313 M, R492X) , both located in the kinase domain. Matenia et al.  found that microtubule affinity regulating kinase 2 (MARK2) can phosphorylate PINK1, and Thr313 was proved to be the phosphorylation site. When T313 M mutation occurs, PINK1 cannot be phosphorylated, leading to mitochondrial toxicity and abnormal distribution in nerve cells. Arg492 is located at the junction of PINK1 protein kinase domain and the carboxyl terminus. R492X mutation can cause the loss of the entire carboxyl terminal, altering PINK1 kinase activity [6, 17].
There has been no report on the identification of PINK1 autophosphorylation sites in vitro studies and the effect on physiological functions brought by the changes of these sites. Our study demonstrated that Ser465 was one of the autophosphorylation sites in PINK1. The autophosphorylation of PINK1 protein can affect its kinase activity, protein stability, as well as the interaction with Parkin. PINK1 causative mutations T313 M and R492X may cause PD by affecting its kinase activity and interaction with Parkin.
293A human embryonic kidney cells, pGEX-5X-1 vector, pKH3-PINK1 and EGFP-Parkin plasmid were provided by the school of Life Science of University of Science and Technology in China. pKH3-PINK1-T313 M, pKH3-PINK1-R492X and pGEX-5X-1-PINK1 plasmids were constructed in our previous work [3, 22]. pGEX-5X-1-PINK1-T313 M, pGEX-5X-1-PINK1-R492X, pGEX-5X-1-PINK1-S465A, pGEX-5X-1-PINK1-S465D, pKH3-PINK1-S465A and pKH3-PINK1- S465D plasmids were all constructed by this study.
Protein expression and purification in E. coli
We used the same method to induce prokaryotic plasmid expression and purify protein as described in a previous study [3, 22]. A small amount of GST-PINK1 bacteria (112–581 aa) were inoculated into a 600 mL culture medium (AMP+), incubated at 37 °C, 250 rpm. When OD values reached between 0.4–0.6, 100 μl IPTG was added to the culture and incubated for 3 h under the same condition. Resuspended the culture with 1XPBS, followed by sonication, then a crude supernatant was obtained. The protein extract was purified with G4B purification column. SDS-PAGE was used to identify the purified protein, followed by Coomassie brilliant blue staining.
Kinase assay and mass spectrometry
Autophosphorylation of recombinant PINK1 protein was performed in the reaction system containing 2.4 μL of 10X kinase reaction buffer, 19.6 μL of GST-PINK1 purified protein supernatant, 2 μL of 10 mM ATP. Then the mixture was incubated in 30 °C water bath for 1.5 h. All the phosphorylated proteins were denatured by 5XSDS, heating at 100 °C for 5 min, resolved by SDS-PAGE, followed by brilliant coomassie blue R250 staining for 30 min and decolorizing for 5 min. Excised gel slices containing desired bands, can be stored at 4 °C and sent for mass spectrometry analysis.
The proteins were purified by the same method described before. 2.4 μL of 10X kinase reaction buffer, 19.6 μL of purified protein supernatant, 10 μCi of [γ-32P] ATP were added, and incubated in 30 °C water bath for 30 min. Then 5XSDS was added, and boiled at 100 °C for 5 min. SDS-PAGE was carried out as described previously, and protein bands were stained with brilliant coomassie blue R250 for 5 min, and decolorized for another 5 min. The plastic wrapped gel and a film in the X-ray film cassette were placed in a dark room. The film was exposed at −80 °C for 8-16 h, followed by developing and fixing.
Cell culture and transfection
The 293A cells were maintained in the medium containing 10% fetal bovine serum, 100 U/ml penicillin and 100 U/ml streptomycin, and incubated at 37 °C in a CO2 incubator. Plasmid transfection was performed according to the Lipofectamine®2000 protocol.
The immunocytochemical staining of eukaryotic plasmid cells was conducted with the method used in previous articles [3, 22]. The cultured cells were fixed with 4% paraformaldehyde. 0.25% TritonX-100/PBS was used for permeabilization. The samples were blocked in 1% FBS/PBS, and incubated with primary antibody and Rhodamine fluorophores conjugated secondary antibodies. Counterstaining with DAPI, the fluorescence was observed under the inverted fluorescence microscope, then images were captured.
After cell transfection for 24-36 h, each well was added with 100 μg/mL CHX (cycloheximide, CHX). Cells were collected at 0 h, 1 h, 2 h and 3.5 h after the addition of CHX. Total protein was extracted for Western analysis to detect the degradation of the interested protein.
All statistical data were calculated and analyzed using SPSS Statistics 13.0 software. All error bars were expressed as mean ± s.d.. The statistical significance of differences was evaluated by one-way ANOVA, followed by student’s t-test.
Identification of PINK1 protein autophosphorylation site(s) with mass spectrometry
PINK1 protein autophosphorylation level can be weakened by silencing S465 phosphorylation site
Both disease-causing mutant PINK1 protein and Ser465A mutant PINK1 protein decrease its kinase activity
S465 has no influence on PINK1 subcellular localization
S465 phosphorylation site affects PINK1 degradation
Both disease-causing mutant PINK1 protein and Ser465A mutant PINK1 protein affect Parkin subcellular localization
The dynamic changes of protein play a key role in life, as they can achieve the physiological function through various post-translational modifications, among which, reversible protein phosphorylation is a common and crucial one. In mammals, there are about 30% of the proteins going on with phosphorylation process. A variety of biological processes are closely related to post-translational protein phosphorylation, which has been playing an on/off regulation in numerous biochemical functions, such as transcriptional regulation, signal transduction, DNA repair, apoptosis regulation. Therefore, the phosphorylation of proteins is an essential part in intracellular signaling transduction.
In our experiment, we used in vitro phosphorylation studies to exclude the possibilities of PINK1 phosphorylated by other proteins, adopted a liquid chromatography mass spectrometry to identify the Ser465 site as the PINK1 protein autophosphorylation site. Since phosphorylation is a reversible process, the loss of phosphate groups was possible under the experimental conditions. In addition, the phosphorylated peptides were relatively little compared with non-phosphorylated peptides, which could be concealed easily when identified in the mass spectrometry, leading to the false negative results. Therefore, besides Ser465 site, there may be other unidentified PINK1 autophosphorylation sites.
In order to identify whether Ser465 was the PINK1 autophosphorylation site or not, we firstly constructed Ser465 autophosphorylation silent type pGEX-5X-1-PINK1-S465A, replacing the serine residue (S) with alanine residue (A) which cannot be phosphorylated, using the site-directed mutagenesis. After Ser465 being silenced, the PINK1 protein autophosphorylation level was decreased, but not completely blocked, indicating that Ser465 is just one of the PINK1 autophosphorylation sites.
Our study found that the inactivation of Ser465 can down-regulate the kinase activity of PINK1. Together with Ser465A, T313 M and R492X mutant PINK1 also decrease kinase activity in vitro, both of which are disease-causing mutations of PINK1, implying that decreased kinase activity may contribute to PD. However, experiments in vitro cannot fully simulate the phosphorylation process of eukaryotic cells in vivo, and the specific mechanism remains to be further studied.
When we transfected two pKH3-PINK1 mutants in HEK293 cells, HA-PINK1-S465A and HA-PINK1-S465D, there were no significant changes of subcellular localization of PINK1, still displaying the mitochondrial localization. These results suggest that the Ser465 site has no effect on PINK1 subcellular localization. PINK1 protein is an integral membrane protein, mainly located in the mitochondria. It has already shown that PINK1 protein localizes in mitochondria cristae, and both wild-type and mutant (outside the mitochondrial localization domain) PINK1 protein distribute in the same way in cells, indicating that PINK1 mutation outside the mitochondrial localization domain does not affect its subcellular localization . As a mitochondrial-located kinase, PINK1 plays a key role in maintaining the normal function of mitochondria and protecting the mitochondria from oxidative stress.
Our study found that Ser465 phosphorylation was also related to the PINK1 degradation. Both disabled or excessive PINK1 phosphorylation can slow down the PINK1 degradation, increase the intracellular concentration of PINK1. A proper concentration of PINK1 is required to maintain mitochondrial homeostasis. Most studies have found that PINK1 mainly maintains normal mitochondrial morphology and function, reduces mitochondrial dysfunction under stress, inhibits apoptosis, and is a neuron protective protein ([1, 4, 5, 13, 15]). Some studies have demonstrated that PINK1 protein degrades primarily by the ubiquitin-proteasome degradation pathway, but so far the related E3 ligase in the pathway remains unclear [16, 19, 23], which may be associated with the PINK1 autophosphorylation.
Our study also investigated the influence of PINK1 autophosphorylation on Parkin. Both wild-type PINK1 protein and S465D mutant protein can promote the transfer of Parkin to clustered mitochondria, while S465A, T313 M, R492X mutant PINK1 had a relatively weaker role in the interaction with Parkin. S465A mutant can disable the autophosphorylation of PINK1, repressing the transfer process; While mutant S465D possesses the phosphorylation ability, completing the same process as the wild-type protein. We can infer that PINK1 autophosphorylation contributes to the transit of Parkin to mitochondria. For the S465A, T313 M and R492X mutant protein, the inhibition of transfer process may be related to the reduced kinase activity. Some studies have also confirmed that PINK1 can phosphorylate Parkin and jointly transfer to the mitochondria, which were gathered in clusters around the nucleus. The decreased kinase activity of these mutant PINK1 proteins may lead to the abnormal physiological processes.
In summary, protein phosphorylation is a crucial aspect of intracellular signaling. Our study elucidated that PINK1 protein autophosphorylation can affect its kinase activity and protein stability, and influent PINK1 and Parkin protein interaction. We also included two PINK1 causative mutations in our study, T313 M and R492X, which can decrease the kinase activity and affect the interaction with Parkin in the same way as Ser465A, hinting that the change of autophosphorylation activity of PINK1 may be one of the mechanisms of the two disease-causing mutations.
We would like to thank all individuals participating in the study.
This work was supported by grant 2016YFC1306000, 2017YFC0909100 from the national key plan for scientific research and development of China, grants 81430023, 81371405, 81571248 from the National Natural Science Foundation of China, grant 2016CX025 from innovation-driven plan of Central South University,grant 2017JJ1037 from Hunan Science Funds for Distinguished Young Scholar.
Availability of data and materials
The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.
BT, XY and JG conceived of the study, and participated in the coordination and helped to draft the manuscript. LY, QS carried out the identification of the autophosphorylation and following functional study, participated in the data analysis. YC, YY and QX participated in the manuscript draft and interpretation of data. All authors read and approved the final manuscript.
Ethics approval and consent to participate
Consent for publication
The authors declare that they have no competing interests.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- Beilina A, Van Der Brug M, Ahmad R, Kesavapany S, Miller DW, Petsko GA, Cookson MR. Mutations in PTEN-induced putative kinase 1 associated with recessive parkinsonism have differential effects on protein stability. Proc Natl Acad Sci U S A. 2005;102:5703–8.View ArticlePubMedPubMed CentralGoogle Scholar
- Cannon JR, Greenamyre JT. Gene-environment interactions in Parkinson's disease: specific evidence in humans and mammalian models. Neurobiol Dis. 2013;57:38–46.View ArticlePubMedGoogle Scholar
- Che X, Tang B, Wang X, Chen D, Yan X, Jiang H, Shen L, Xu Q, Wang G, Guo J. The BAG2 Protein Stabilises PINK1 By Decreasing its Ubiquitinationion. Biochem Biophys Res Commun. 2013;441:488–92.View ArticlePubMedGoogle Scholar
- Cookson MR, Dauer W, Dawson T, Fon EA, Guo M, Shen J. The roles of kinases in familial Parkinson's disease. J Neurosci. 2007;27:11865–8.View ArticlePubMedGoogle Scholar
- Giasson BI. Mitochondrial injury: a hot spot for parkinsonism and Parkinson's disease? Sci Aging Knowl Environ. 2004;2004:pe42.View ArticleGoogle Scholar
- Guo JF, Xiao B, Liao B, Zhang XW, Nie LL, Zhang YH, Shen L, Jiang H, Xia K, Pan Q, Yan XX, Tang BS. Mutation analysis of Parkin, PINK1, DJ-1 and ATP13A2 genes in Chinese patients with autosomal recessive early-onset Parkinsonism. Mov Disord. 2008;23:2074–9.View ArticlePubMedGoogle Scholar
- Kalia LV, Lang AE. Parkinson's disease. Lancet. 2015;386:896–912.View ArticlePubMedGoogle Scholar
- Kim Y, Park J, Kim S, Song S, Kwon SK, Lee SH, Kitada T, Kim JM, Chung J. PINK1 controls mitochondriallocalization of Parkin through direct phosphorylation. Biochem Biophys Res Commun. 2008;377:975–80.View ArticlePubMedGoogle Scholar
- Matenia D, Hempp C, Timm T, Eikhof A, Mandelkow EM. Microtubule affinity-regulating kinase 2 (MARK2) turns on phosphatase and tensin homolog (PTEN)-induced kinase 1 (PINK1) at Thr-313, a mutation site in Parkinson disease: effects on mitochondrial transport. J Biol Chem. 2012;287:8174–86.View ArticlePubMedPubMed CentralGoogle Scholar
- Meissner C, Lorenz H, Weihofen A, Selkoe DJ, Lemberg MK. The mitochondrial intramembrane protease PARL cleaves human Pink1 to regulate Pink1 traicking. J Neurochem. 2011;117:856–67.View ArticlePubMedGoogle Scholar
- Nakajima A, Kataoka K, Hong M, Sakaguchi M, Huh NH. BRPK, a novel protein kinase showing increased expression in mouse cancer cell lines with higher metastatic potential. Cancer Lett. 2003;201:195–201.PubMedGoogle Scholar
- Okatsu K, Oka T, Iguchi M, Imamura K, Kosako H, Tani N, Kimura M, Go E, Koyano F, Funayama M, Shiba-Fukushima K, Sato S, Shimizu H, Fukunaga Y, Taniguchi H, Komatsu M, Hattori N, Mihara K, Tanaka K, Matsuda N. PINK1 autophosphorylation upon membrane potential dissipation is essential for Parkin recruitment to damaged mitochondria. Nat Commun. 2012;3:1016.View ArticlePubMedPubMed CentralGoogle Scholar
- Petit A, Kawarai T, Paitel E, Sanjo N, Maj M, Scheid M, Chen F, Gu Y, Hasegawa H, Salehi-Rad S, Wang L, Rogaeva E, Fraser P, Robinson B, St George-Hyslop P, Tandon A. Wild-typePINK1 prevents basal and induced neuronal apoptosis, a protective effect abrogated by Parkinson disease-related mutation. J Biol Chem. 2005;280:34025–32.View ArticlePubMedGoogle Scholar
- Pridgeon JW, Olzmann JA, Chin LS, Li L. PINK1 protects against oxidative stress by Phosphorylating mitochondrial chaperone TRAP1. Plos Bio. 2007;5:1494–503.View ArticleGoogle Scholar
- Schapira AH. Mitochondrial involvement in Parkinson's disease, Huntington's disease, hereditary spastic paraplegia and Friedreich's ataxia. Biochim Biophys Acta. 1999;1410:159–70.View ArticlePubMedGoogle Scholar
- Shiba K, Arai T, Sato S, Kubo S, Ohba Y, Mizuno Y, Hattori N. Parkin stabilizes PINK1 through direct interaction. Biochem Biophys Res Commun. 2009;383:331–5.View ArticlePubMedGoogle Scholar
- Silvestri L, Caputo V, Bellacchio E, Atorino L, Dallapiccola B, Valente EM, Casari G. Mitochondrial import and enzymatic activity of PINK1 mutants associated to recessive parkinsonism. Hum Mol Genet. 2005;14:3477–92.View ArticlePubMedGoogle Scholar
- Sim CH, Lio DS, Mok SS, Masters CL, Hill AF, Culvenor JG, Cheng HC. C-terminal truncation and Parkinson's disease-associated mutations down-regulate the protein serine/threonine kinase activity of PTEN-induced kinase-1. Hum Mol Genet. 2006;15:3251–62.View ArticlePubMedGoogle Scholar
- Um JW, Stichel-Gunkel C, Lübbert H, Lee G, Chung KC. Molecular interaction between parkin and PINK1 in mammalian neuronal cells. Mol Cell Neurosci. 2009;40:421–32.View ArticlePubMedGoogle Scholar
- Valente EM, Abou-Sleiman PM, Caputo V, Muqit MM, Harvey K, Gispert S, Ali Z, Del Turco D, Bentivoglio AR, Healy DG, Albanese A, Nussbaum R, González-Maldonado R, Deller T, Salvi S, Cortelli P, Gilks WP, Latchman DS, Harvey RJ, Dallapiccola B, Auburger G, Wood NW. Hereditary early-onset Parkinson's disease caused by mutations in PINK1. Science. 2004;304:1158–60.View ArticlePubMedGoogle Scholar
- Volta M, Milnerwood AJ, Farrer MJ. Insights from late-onset familial parkinsonism on the pathogenesis of idiopathic Parkinson's disease. Lancet Neurol. 2015;14:1054–64.View ArticlePubMedGoogle Scholar
- Wang X, Guo J, Fei E, Mu Y, He S, Che X, Tan J, Xia K, Zhang Z, Wang G, Tang B. BAG5 protects against mitochondrial oxidative damage through regulating PINK1 degradation. PLoS One. 2014;9:e86276.View ArticlePubMedPubMed CentralGoogle Scholar
- Xiong H, Wang D, Chen L, Choo YS, Ma H, Tang C, Xia K, Jiang W, Ronai Z, Zhuang X, Zhang Z. Parkin, PINK1, and DJ-1 form a ubiquitin E3 ligase complex promoting unfolded protein degradation. Parkin, PINK1, and DJ-1 form a ubiquitinE3 ligase complex promoting unfolded protein degradation. J Clin Invest. 2009;119:650–60.View ArticlePubMedPubMed CentralGoogle Scholar